Chendu DIAO Pharmaceutical Group

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 Diabetes

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
DA-302168SPhase 3Overweight and Obesity
Est. primary completion 2027-07-09 · NCT07629544 · CT.gov ↗
What to watch
October 2027 (1)
DA-302168SPhase 2Type 2 Diabetes Mellitus
Est. primary completion 2027-10-20 · NCT07755150 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.